Takeaways: Kashiv BioSciences gets a key regulatory step for its XOLAIR (omalizumab) biosimilar, ADL-018. The market implication is a likely cost-reduction play in a high-value o...
Takeaways Optimi is using its Nasdaq uplist and 1‑for‑30 share consolidation to raise roughly 15 million US dollars at scale, then plow the cash into making and selling ...
For most of modern medicine, the pharmaceutical industry has operated largely within a reactive healthcare model, developing therapies designed to treat diseases after they emerge. Today, however, adv...
The world’s population is aging at an unprecedented pace, creating one of the most significant long term shifts in global healthcare demand. By the coming decades, older adults will represent an incre...
The pharmaceutical industry has historically operated as one of the world’s most globally interconnected sectors, relying on international supply chains, cross border research collaboration, and multi...
Healthcare is undergoing a major cultural and commercial shift as patients become more informed, digitally connected, and actively involved in their care decisions. What was once a largely physician d...
Biosimilars were introduced with the promise of expanding access to biologic therapies while reducing healthcare costs. As more blockbuster biologics lose exclusivity, biosimilars are becoming an incr...
For decades, women’s health remained one of the most underfunded and underserved areas in healthcare despite representing half the global population. Many conditions affecting women received limited r...
Contract development and manufacturing organizations, often referred to as CDMOs, were once viewed primarily as outsourced service providers supporting pharmaceutical production. Today, their role is ...
As the pharmaceutical industry becomes increasingly digital, cybersecurity is emerging as one of the sector’s most urgent and underestimated risks. Clinical trials, manufacturing operations, supply ch...
